Table 1 Safety population patient characteristics: dose escalation
Baseline Demographics & Disposition | N = 29 |
|---|---|
sex, n (%) | |
Male | 18 (62) |
Female | 11 (38) |
Age, median years (range) | 53 (22–72) |
Histology, n (%) | |
MM | 11 (37.9) |
Lymphoma | 18 (62) |
Subtype, n (%) | |
DLBCL | 11 (37.9) |
FL | 3 (10.3) |
Large B-cell lymphoma | 1 (3.4) |
cHL | 1 (3.4) |
PTCL-NOS | 1 (3.4) |
AITL | 1 (3.4) |
Stage of MM, n (%) | |
II | 1 (9.1) |
III | 10 (90.9) |
Stage of DLBCL, n (%) | |
I–II | 1 (9.1) |
III–IV | 10 (90.9) |
No. prior regimens, median (range) | |
MM | 3 (1–7) |
Lymphoma | 2 (1–4) |
Prior therapy of MM, n (%) | |
Lenalidomide, Bortezomib, Dexamethasone | 11 (100) |
Daratumumab | 3 (27.3) |
Autologous Stem Cell Transplantation | 2 (18.2) |
BCMA-CAR-T | 1 (9.1) |
Prior therapy of DLBCL, n (%) | |
Chidamide+RCHOP | 2 (18.2) |
Autologous stem cell transplantation | 2 (18.2) |
